Why did you participate in the Biomapas Academy?
Everything started when I had a trip to a career fair during my studies. This was the first time I met Biomapas in person as there were several lecturers that presented the company itself and its activities. I remember thinking that I would like to work with this team as it piqued my interest.
Later, when I was working on my master’s degree, I came across an advertisement on social media for the Biomapas Academy. I already knew that I wanted to learn more about the pharma industry and was interested in various opportunities, so I applied for this opportunity.
How was your experience during the three months?
The Academy was a continuous cycle spanning several months of interesting lectures from true professionals with extensive knowledge. During this short time, I learned a lot about product development, research, safety information and its systems, different possible roles and their responsibilities, and new opportunities where young specialists can grow and find their place in the life sciences industry.
What did the future hold for you after the Academy?
A while after the Academy, I officially became part of Biomapas and its big family! With my background being an MPharm, I was always interested in drug safety. Therefore, I am working in the Pharmacovigilance Department as a Pharmacovigilance Project Management Assistant. I must say there are many interesting things to learn and experience that I am looking forward to with my team.
What would you say to the future participants?
If you are thinking about participating in the Academy, do not hesitate. Being an alumnus, I can say that you will definitely see the pharma industry from within. It will broaden your understanding; you will gain needed knowledge and experience in life sciences and will be able to apply that information working in your chosen field. I hope to see you at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Pharmacovigilance in the MENA Region
This blog focuses on pharmacovigilance (PV) in the MENA Region; the Middle East and North Africa. We do this by comparing the MENA region and Europe and inter-country differences in the MENA region. Local legislation and requirements will be discussed, such as...
How to prepare an eye-catching resume?
Everything has a start, right? Well, the start of your career can become a good and professional resume, or sometimes better known as a CV, Curriculum vitae. It’s often one of the first things recruiters look at when you are applying for a job or an internship. In...
Selecting a Pharmacovigilance Drug Safety Database
Selecting a Pharmacovigilance Drug Safety Database The WHO defines pharmacovigilance (PV) as the science and activities related to detecting, assessing, understanding, and preventing adverse effects of a medicinal product or any other possible drug-related problems. A...
How does the conflict between UA & RU impact the pharma industry?
Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And with good reason. Russia's invasion of Ukraine affects millions of people, not just in this Eastern European nation but...
How does the Russian invasion impact the pharmaceutical industry?
Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And, with good reason. Russia's invasion of Ukraine affects millions of people, not just in this Eastern European nation but...
How To Manage An Early Phase Oncology Study: Project Manager Insights
Clinical development of oncology drugs has one of the lowest success rates of the development of Investigational New Drugs (INDs) for all disease categories, with less than 7% of phase I-tested oncology drugs achieving market approval. Moreover, the clinical...
Biomapas Announces Two New Appointments to Board of Directors
February 2022 Biomapas, a full spectrum clinical, regulatory, pharmacovigilance and medical information solution provider, is pleased to announce the two new members joining its board of directors. Coming from life science, biopharmaceutical and financial industries,...
How To Improve Patient Recruitment In Early Phase Oncology Trials
The difficulties of recruiting in clinical trials, and particularly cancer patients in their early stages, can significantly obstruct the development of innovative treatments. There is an undeniable increase in demand for Early Phase Clinical studies in patients to...
What are the advantages of a hospital-based Early Phase Unit?
Choosing the right setting for your early phase trial can be challenging. As a sponsor, it's natural to remain cautious about running more extensive early-phase patient trials in a single Phase I unit due predominantly to the doubt over actually being able to recruit...
Smooth Switch to the EAEU Marketing Authorization for Medicinal Products
Webinar: Smooth Switch to the EAEU Marketing Authorization for Medicinal Products The webinar will highlight the practical tips and guide you through the crucial steps of marketing authorization upgrade to the Eurasian Economic Union (EAEU) one, ultimately leading you...
